| Followers | 28 |
| Posts | 20902 |
| Boards Moderated | 0 |
| Alias Born | 01/16/2026 |
Tuesday, April 28, 2026 8:16:01 AM
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
April 28, 2026 8:05 AM
PR Newswire (US)
SOUTH SAN FRANCISCO, Calif., April 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit? www.rigel.com.
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email:?david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2026-financial-results-302754902.html
SOURCE Rigel Pharmaceuticals, Inc.
Original: Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Recent RIGL News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 02:43:17 PM
- Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress • PR Newswire (US) • 05/21/2026 09:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:10:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 12:50:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 12:50:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 12:49:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 12:49:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 12:49:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 12:48:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 12:48:13 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 03:33:26 PM
- Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference • PR Newswire (US) • 05/14/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 09:24:38 PM
- Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer • PR Newswire (US) • 05/12/2026 11:00:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/07/2026 09:01:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:08:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 08:05:51 PM
- Rigel Reports First Quarter 2026 Financial Results • PR Newswire (US) • 05/05/2026 08:01:00 PM
- Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results • PR Newswire (US) • 04/28/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 08:18:08 PM
- Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 04/07/2026 12:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/03/2026 08:02:41 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/03/2026 08:01:59 PM
- Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology • PR Newswire (US) • 03/31/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:11:12 PM

